Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

摘要

BackgroundPandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between GlaxoSmithKline Vaccines’ A/California/7/2009 (H1N1)v-like-AS03 vaccines manufactured in Dresden (D-Pan), and Quebec (Q-Pan).